



CERAMENT® | Antibiotic eluting bone substitutes

Personalize a solution for your patients needs


- Remodel into bone^{1,6}
- Protect bone healing^{1,2,3,4}
- In a clinical study of CERAMENT® | G^{3,4,5}
 - Long-term solution
 - Reduced risk of infection recurrence
 - Reduced risk of fracture

CERAMENT® ∨	Article number	A0451-03	10mL
CERAMENT ® G	Article number	A0450-01	10mL
CERAMENT ® G	Article number		



BONESUPPORT AB Ideon Science Park, Scheelevägen 19 SE-223 70 Lund, Sweden T: +46 46 286 53 70 F: +46 46 286 53 71 E: info@bonesupport.com

www.bonesupport.com




The only CE-marked injectable antibiotic eluting bone substitutes




Effective antibiotic elution

CERAMENT® | G with gentamicin **CERAMENT®** ∨ with vancomycin

- Antibiotic elution above Minimum Inhibitory Concentration (MIC) for at least 28 days for gentamicin and vancomycin sensitive micro-organisms
- Not surface area dependant: injected, beads or molded






Proven rapid bone remodeling

A unique combination of hydroxyapatite and calcium sulfate

Impressive clinical outcomes

In a clinical study of **CERAMENT**®|G after min. 1 year^{3,4}

- 96% eradication of infection
- 75% of patients have complete defect filling at 6 months
- 3% fracture rate



- a) Immediately post operative: **CERAMENT**® | G is clearly seen filling alarge tibial bone void.
- b) 44 weeks: there is almost no **CERAMENT**[®]|G visible and there is evidence of organized trabecular bone.

Easy to mix and use

Consistent, safe handling

- Mix for 30 seconds in a ready-to-use closed mixing system
- Isothermic
- Not temperature sensitive
- Self-setting
- Injectable or can be molded into beads
- Comes with two extender tips



Promote and protect bone healing

- 1. Antibiotic elution and bone remodelling with a novel bone substitute impregnated with gentamicin, F Lindberg. European Bone and Joint Infection Society (EBJIS) 2012. Podium Presentation*.
- 2. In vitro characterization of a vancomycin eluting injectable bone graft substitute with examination of concomitant bone remodeling in a rabbit model. Eva C. Lidén, Veronica R. Sandell, Argyrios Kasioptas B. Fredrik Lindberg. European Bone and Joint Infection Society (EBJIS) 2014. Podium presentation*
- 3. A prospective clinical outcome study of a new biphasic absorbable composite carrier with Gentamicin in the treatment of chronic osteomyelitis. M McNally, J Ferguson, R Giordamaina, N Jacobs, M Sutherland, D Stubbs, A Woodhouse. 33rd Congress of the European Bone and Joint Infection Society (EBJIS). Abstract F093 Podium Presentation. *Pre-clinical studies are not necessarily indicative of clinical performance.
- 4. Single-stage treatment of chronic osteomyelitis with a new absorbable, gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite A prospective series of 100 cases. M. A. McNally, J. Y. Ferguson, A. C. K. Lau, M. Diefenbeck, M. Scarborough, A. J. Ramsden, B. L. Atkins. Bone Joint J 2016;98-8:1289-96.
- 5. A comparative study of three bioabsorbable antibiotic carriers in chronic osteomyelitis: 313 patients with minimum one-year follow-up. M. McNally, J. Ferguson, J. Kendall, M. Dudareva, Scarborough, D. Stubbs. European Bone and Joint Infection Society (EBJIS) 2015, Podium presentation, Free paper #135.
- 6. Kaczmarczyk et al. Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study. BMC Musculoskeletal Disorders (2015) 16:369. DOI 10.1186/s12891-015-0828-3